Yili "Mei Yi Tian" active lactobacillus drink
Dietary Supplement100ml of Yili "Mei Yi Tian" active lactobacillus drink to be taken once per day at 10am daily during the 84-days intervention
NCT Number: NCT01677715
Study on Evaluating the Promote Effect of Yili Mei Yi Tian Active Lactobacillus Drink on Immunity and Physical Intestinal Canal
Looking for future studies?
Notify Me25 year–45 year
All sexes
Interventional
Not applicable
NanMoFang Community Health Service Center, ChaoYang District, Beijing Municipality, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
100ml of Yili "Mei Yi Tian" active lactobacillus drink to be taken once per day at 10am daily during the 84-days intervention
100ml of recombined milk drink contains no lactobacillus to be taken once per day at 10am daily during the 84-days intervention
Time frame: Baseline & 3 months
Time frame: 3 months
Time frame: Baseline & 3 months
Time frame: Baseline & 3 months
Inner Mongolia Yili Industrial Group Co., Ltd
Industry
Study on Evaluating the Promote Effect of Yili Mei Yi Tian Active Lactobacillus Drink on Immunity and Physical Intestinal Canal
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01677702
Common Cold, Human Influenza
Chao Yang District, Beijing Municipality, China
View Trial DetailsNCT02200276
Immunization, Infections
Baltimore, Maryland, United States
View Trial DetailsNCT06694025
Immunization, Infections
Seoul, Seoul-teukbyeolsi, South Korea
View Trial DetailsNCT04936776
Hematologic Diseases, Hemic and Lymphatic Diseases
New York, United States
View Trial Details